Fritextsökning
Innehållstyper
-
Matti Sällberg om året som kommer: ”Större intresse riktas mot Europa”
Nu nalkas vinterns ledigheter. Det vill Life Science Sweden uppmärksamma genom att ställa bakåt- och framåtblickande frågor till branschprofiler fram till jul. ...
-
Carl Zeiss Meditec achieves revenue growth and stable operating profit
Further recovery in order entry compared to prior year.
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
-
Verigraft fick Arvid Carlsson-priset
Göteborgsbaserade Verigraft belönas med Arvid Carlsson Award 2025 för ”banbrytande framsteg inom regenerativ medicin”.
-
Anna Törner: ”If I fall seriously ill, I’ll move to Finland”
”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.
-
Your solution for right part positioning
ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.
-
Quality assurance for research and development of medical devices
Overcome the hurdles of research, development, and QA lab environments within the regulated medical technology industry.
-
From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool
Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals...
-
Discover ZEISS ZEN core – now for electron microscopy
Watch the recording of our free webinar.
-
FDA plans to replace animal testing with AI – “Paradigm shift”
The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met...
-
Final assembly inspection of medical plastics
Technical paper by ZEISS Medical Industry Solutions.
-
Automated nitrogen analysis reduces costs per sample
N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo
-
The race between new alzheimer’s drugs Kisunla and Leqembi heats up
Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...
-
Förbättra din maskinsäkerhet med SMC:s nya avluftande säkerhetsventil för höga flöden
SMC lanserar säkerhetsventilen VPX, utformad för att hantera större pneumatiska system. Ventilen är framtagen för nödstoppssituationer där tryck ska avluftas oc...
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...
-
KI’s new super machine measures brain activity in real-time – “A very expensive hairdo”
Using brand-new, super-advanced equipment, researchers at Karolinska Institutet can now measure brain activity in real-time, with higher resolution than previou...
-
Wegovy approved in the U.S. for treatment of liver disease
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s drug Wegovy to treat the serious liver condition known as MASH. ...
-
Radioactive tracer to measure effect of drug towards Crohn’s disease
A radioactive tracer developed by Astra Zeneca and the Karolinska Institutet may play a major role for patients with Crohn's disease. That is the belief of Mari...
-
ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.
-
The Top 10 Challenges Facing Laboratories Today
Navigating the Laboratory Automation Landscape
-
Webinar: Automate your processes
Free ZEISS webinar on January 30th, 2025.
-
The Future of Swedish & Danish Life Science (2026)
-
Danska Genmab köper cancerbolag för 75 miljarder
Läkemedelsbolaget Genmab köper nederländska Merus, som utvecklar cancerterapier, för 8 miljarder dollar, motsvarande närmare 75 miljarder kronor.
-
Health politician Lina Nordquist: ”I find it hard to be idle”
She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decid...